Association of galectin-3 with changes in left ventricular function in recent-onset dilated cardiomyopathy

References

• Aoki, T., et al., 2011. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure—comparison between preserved and reduced ejection fraction heart failure. Circulation journal, 75(11), 2605–2613.
   PubMed Web of Science ®Google Scholar
• Assomull, R. G., et al., 2006. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. Journal of the American college of cardiology, 48(10), 1977–1985.
   PubMed Web of Science ®Google Scholar
• Besler, C., et al., 2017. Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker. Circulation: heart failure, 10(3)
   PubMedGoogle Scholar
• Cerit, L., 2017. All roads lead to Rome: myocardial fibrosis. JACC Heart failure, 5(6), 468.
   PubMed Web of Science ®Google Scholar
• De Boer, R. A., et al., 2009. Galectin-3: a novel mediator of heart failure development and progression. European journal of heart failure, 11(9), 811–817.
   PubMed Web of Science ®Google Scholar
• Gyongyosi, M., et al., 2017. Myocardial fibrosis: biomedical research from bench to bedside. European journal of heart failure, 19(2), 177–191.
   PubMed Web of Science ®Google Scholar
• Leong, D. P., et al., 2012. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. European heart journal, 33(5), 640–648.
   PubMed Web of Science ®Google Scholar
• Lok, D. J., et al., 2013. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical research in cardiology, 102(2), 103–110.
   PubMed Web of Science ®Google Scholar
• Lopez, B., et al., 2015. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. Journal of American college of cardiology, 65(22), 2449–2456.
   PubMed Web of Science ®Google Scholar
• Lopez-Andres, N., et al., 2012. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. European journal of heart failure, 14(1), 74–81.
   PubMed Web of Science ®Google Scholar
• Lupon, J., et al., 2017. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. European journal of heart failure, 19(12), 1615–1623.
   PubMed Web of Science ®Google Scholar
• Mann, D. L., Barger, P. M., and Burkhoff, D., 2012. Myocardial recovery and the failing heart: myth, magic, or molecular target? Journal of the American college of cardiology, 60(24), 2465–2472.
   PubMed Web of Science ®Google Scholar
• Masci, P. G., et al., 2014. Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure. Circulation. Heart failure, 7(3), 448–456.
   PubMed Web of Science ®Google Scholar
• Mcmurray, J. J., et al., 2012. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European heart Journal, 14(8), 803–869.
   Google Scholar
• Merlo, M., et al., 2018. Evolving concepts in dilated cardiomyopathy. European journal of heart failure, 20(2), 228–239.
   PubMed Web of Science ®Google Scholar
• Motiwala, S. R., et al., 2013. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. European journal of heart failure, 15(10), 1157–1163.
   PubMed Web of Science ®Google Scholar
• Ponikowski, P., et al., 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 37(27), 2129–2200.
   PubMed Web of Science ®Google Scholar
• Rapezzi, C., et al., 2013. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European heart journal, 34(19), 1448–1458.
   PubMed Web of Science ®Google Scholar
• Richards, A. M., 2017. Circulating biomarkers of cardiac fibrosis: do we have any and what use are they? Circulation: heart failure, 10(3).
   PubMed Web of Science ®Google Scholar
• Rolf, A., et al., 2009. Immunohistological basis of the late gadolinium enhancement phenomenon in tako-tsubo cardiomyopathy. European heart journal, 30(13), 1635–1642.
   PubMed Web of Science ®Google Scholar
• Shah, R. V., et al., 2010. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European journal of heart failure, 12(8), 826–832.
   PubMed Web of Science ®Google Scholar
• Verdonschot, J., et al., 2018. Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. Circulation heart failure, 11(11).
   Web of Science ®Google Scholar
• Vergaro, G., et al., 2015. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. International journal of cardiology, 184, 96–100.
   PubMed Web of Science ®Google Scholar
• Zannad, F., 2014. What is measured by cardiac fibrosis biomarkers and imaging? Circulation. Heart failure, 7(2), 239–242.
   PubMed Web of Science ®Google Scholar
• Zou, C. H., et al., 2014. Frequency and predictors of normalization of left ventricular ejection fraction in recent-onset nonischemic cardiomyopathy. American journal of cardiology, 113(10), 1705–1710.
   PubMed Web of Science ®Google Scholar